Body size and risk for breast cancer in relation to estrogen and progesterone receptor status in Japan
Body size and risk for breast cancer in relation to estrogen and progesterone receptor status in Japan
复制标题
DOI：
10.1016/j.annepidem.2006.09.003
复制
发表时间：
2007-04-01
影响因子：
5.6
通讯作者：
Tsugane, Shoichiro
中科院分区：
文献类型：
--
作者：
Iwasaki, Motoki;Otani, Tetsuya;Tsugane, Shoichiro
目得：本研究的目的是探讨身高，体重和体重指数（BMI）与乳腺癌及其激素受体定义的亚型在低风险population.METHODS：我们确定了441例新诊断的乳腺癌病例在9.9年的随访人群为基础的队列，包括55,537名妇女，年龄在40至69岁。身体大小进行了评估，通过使用自填questionnaire.RESULTS：我们发现一个显着的正相关的身高和轻微显着的正相关的体重和BMI与乳腺癌绝经后妇女。体重和BMI与绝经后妇女雌激素受体阳性（ER+）乳腺癌的相关性比雌激素受体阴性（ER-）乳腺癌更强。BMI与ER+风险增加显著相关（风险比[HR]/BMI增加1 kg/m（2），1.08; 95%置信区间[CI]，1.01-1.15），但不是ER-乳腺癌（HR/BMI增加1 kg/m（2），0.95; 95% CI，0.84-1.06; HR差异P = 0.048）。目前的研究表明，在日本绝经后妇女中，身高、体重和BMI与乳腺癌风险增加有关。体重和BMI的正相关可能仅限于ER+乳腺癌。
PURPOSE: The aim of this study is to examine the association of height, weight, and body mass index (BMI) with breast cancer and its hormone receptor-defined subtype in a low-risk population.METHODS: We identified 441 newly diagnosed cases of breast cancer during a 9.9-year follow-up of a population-based cohort consisting of 55,537 women aged 40 to 69 years. Body size was assessed by using a self-administered questionnaire.RESULTS: We found a significant positive association of height and marginally significant positive associations of weight and BMI with breast cancer in postmenopausal women. Weight and BMI were associated more strongly with estrogen receptor-positive (ER+) than ER-negative (ER-) breast cancer in postmenopausal women. BMI was related significantly to increased risk for ER+ (hazard ratio [HR] per BMI increment of 1 kg/m(2), 1.08; 95% confidence interval [CI], 1.01-1.15), but not ER- breast cancer (HR per BMI increment of 1 kg/m(2), 0.95; 95% Cl, 0.84-1.06; P for difference of HRs = 0.048).CONCLUSIONS: The present study suggests that height, weight, and BMI are associated with increased risk for breast cancer among postmenopausal women in Japan. The positive association of weight and BMI might be limited to ER+ breast cancer.